Protein / target
Mineralocorticoid receptor
Protein at a glance
Biological role
Sequence-specific double-stranded DNA binding
Primary system
Endocrine & metabolic
Strongest disease association
autosomal dominant pseudohypoaldosteronism type 1
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
13 approved · 4 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels
Subcellular location
Domains and Gene Ontology detail (21)Hide
Domains & features
Gene Ontology
- Cchromatin
- Ccytosol
- Cendoplasmic reticulum membrane
- Cnucleoplasm
- Cnucleus
- Creceptor complex
- FDNA-binding transcription factor activity
- FDNA-binding transcription factor activity, RNA polymerase II-specific
- Festrogen response element binding
- Fnuclear receptor activity
- Fnuclear steroid receptor activity
- Fsequence-specific double-stranded DNA binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Nuclear receptor signalling
- ·DNA-binding transcription factor activity
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
- ·nuclear receptor activity
- ·nuclear receptor-mediated steroid hormone signaling pathway
Transcriptional regulation
- ·DNA-binding transcription factor activity
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
- ·DNA-templated transcription
- ·regulation of transcription by RNA polymerase II
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Mineralocorticoid receptor antagonist
Appears in clinical studies involving hypertensive disorder, nephrotic syndrome, heart failure, myocardial infarction
Mineralocorticoid receptor antagonist
Appears in clinical studies involving cardiovascular disorder, chronic kidney disease, heart failure, chronic kidney disease
Mineralocorticoid receptor antagonist
Appears in clinical studies involving cardiovascular disorder, subarachnoid hemorrhage, cocaine dependence, Mental deterioration
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,324 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 17 total
chronic kidney disease · Hypertension · hypertensive disorder
Hypertension · essential hypertension · hypertensive disorder
diabetic kidney disease · metabolic dysfunction-associated steatohepatitis
cardiovascular disorder · chronic kidney disease · heart failure
primary adrenal insufficiency
primary adrenal insufficiency · adrenogenital syndrome · chronic primary adrenal insufficiency
hypertensive disorder · diabetes mellitus · cardiovascular disorder
acne · Pain · Dysmenorrhea
cardiovascular disorder · acute respiratory distress syndrome · congestive heart failure
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Related literature
Papers indexed under “Receptors, Mineralocorticoid” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 3 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationUpdated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.
- New publicationFinerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
- New publicationGuidelines of care for the management of acne vulgaris.
- Regulatory approval
Approval: Qaialdo (EMA)
- Regulatory approval
Approval: Kerendia (EMA)
- New publicationCardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
- New publicationRegional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
- New publicationCardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
- New publicationSpironolactone for heart failure with preserved ejection fraction.
- New publicationCardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
- New publicationBaseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
- New publicationThe effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.